An interventional study of Exercise in Sarcoma, sponsored by Kira Bloomquist. Not yet recruiting at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-25.
Sponsored by Kira Bloomquist · Not applicable, Interventional, and Supportive care
Among 39 studies in Sarcoma with a site in Denmark — 12 open to participants now, 13 under way, none of them phase 3. Sarcoma · Denmark.
Among the 39 studies in Sarcoma with a site in Denmark, this one is the 35th largest by planned enrollment of the 37 interventional ones, is the only one that started in 2027, is one of 4 with no phase, reaches primary completion later than 8 of the 12 other live ones, and was the 38th registered.
1,607 studies on the registry are indexed under Sarcoma; 366 are open to participants now.
This study's planned enrollment of 16 is below the median of 40 across 1,255 interventional studies indexed under Sarcoma.
Browse Sarcoma studies →12 of the 39 studies in Sarcoma with a site in Denmark are open now, in 12 countries. Each count lists the studies.
Of the 301 Sarcoma studies recruiting now, 191 (63%) set no upper age limit and 83 (28%) stop at 75 or younger; 91 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →39 studies; the count open now beside each. This study's row is marked.
First in 1993; this study’s year is marked. 1 started in 2027.
Median enrollment 128 across the 37 interventional studies, 100 across the 2 observational. Of the 22 that completed or were terminated, 11 (50%) have results posted.
19 of 39 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Kira Bloomquist as lead sponsor.
Kira Bloomquist has 1 study filed under Sarcoma — fewer than ten, so there is no comparison to draw.
1 of the studies in Sarcoma with a site in Denmark that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05840575Rigshospitalet, DenmarkInvestigating Cognitive Impairment in Young Patients With Cancer Prospectively | 2027-03-01 |
Among the 39 studies in Sarcoma with a site in Denmark, from their registry updates:
The main goal of this clinical trial is to determine: 1) the safety and 2) feasibility of moderate-intensity, intra-infusion aerobic exercise in people receiving chemotherapy for non-resected sarcoma and 3) assess whether intra-infusion exercise acutely increases tumor perfusion.
The trial aims to answer the following research questions:
Adverse event data and patient-reported quality-of-life outcomes will be compared to those of a historical control comprising patients who received chemotherapy for sarcoma within three years prior to study initiation.
Participants will:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The first cycle of chemotherapy will be delivered as per usual care. During all subsequent cycles, participants will partake in intra-infusion aerobic exercise (e.g. pedal ergometer, stationary bike). Exercise will follow a 15-minute exercise / 15-minute rest interval, totalling 30 minutes of exercise per hour of infusion. Participants will be monitored using the Borg rate of perceived exertion (RPE) scale (range 6-20) and heart rate monitors. Target intensity will be low (Borg RPE 10-12) for the first five minutes, increasing to moderate intensity (Borg RPE 13-15) for the last ten minutes. As a precautionary measure, only low-intensity exercise will be performed when receiving cytostatic agents known to carry an increased risk of cardiotoxicity (e.g. anthracyclines). Exercise will be supervised by a physical therapist with experience in exercise oncology, alongside oncology nurses as per usual care.
Other: Exercise
See description of study arm
Adverse events
Adverse events will be extracted from medical records (including adjustment to treatment plans, adjunct medications or procedures) and categorized according to the Common Terminology Criteria for Adverse Events, version 5.0. In addition, before and after each infusion, the intra-infusion exercise group will be asked whether they have experienced any harmful or undesirable outcomes, with additional prompts to better understand the severity and impact of such events. Specific adverse events: Cardiac function and skeletal muscle damage: Routine echocardiography data will be extracted from medical records in both groups. Further, serum troponin I levels (a biomarker used in the early detection of cardiotoxicity) and serum creatine kinase (a biomarker routinely used to assess skeletal muscle damage) will be taken in conjunction with routine blood work in the exercise group.
Time frame: From the commencement of chemotherapy and up to six months post-chemotherapy. As sarcomas are a heterogeneous group of cancers, chemotherapy regimens, including duration, will vary between participants.
Feasibility: recruitment rate
Feasibility of intra-infusion exercise will be assessed by analyzing the number accepting participation in intra-infusion exercise vs. number eligible
Time frame: From initiation of participant recruitment in the department until recruitment of last participant. Anticipated within one year.
Feasibility: retention rate
Feasibility of intra-infusion exercise will be asessed by analyzing the number of participants who remained in the study vs. number enrolled.
Time frame: From the first intra-infusion exercise session to the end of chemotherapy treatment (or up to 6 months if treatment continues beyond 6 months).
Feasibility: attendance rate
Feasibility of intra-infusion exercise be assessed by analyzing the number of intra-infusion exercise sessions completed vs. number possible.
Time frame: From the first intra-infusion exercise session to the end of chemotherapy treatment (or up to 6 months if treatment continues beyond 6 months).
Feasibility: Adherence exercise intensity
Feasibility of intra-infusion exercise will be assessed by analyzing the number of exercise sessions meeting exercise intensity target vs. number of exercise sessions possible.
Time frame: From the first intra-infusion exercise session to the end of chemotherapy treatment (or up to 6 months if treatment continues beyond 6 months).
Tumor perfusion
In the intra-infusion exercise group, tumor perfusion under resting and exercise conditions will be assessed prior to initiating chemotherapy using single-photon emission computed tomography and computed tomography (SPECT/CT) with radioactive tracer (99mTc-Sestamibi (MIBI)). During exercise conditions, participants will be injected intravenously with MIBI at the end of a 15-minute exercise session (moderate target intensity). Because MIBI does not wash out or redistribute significantly, the images captured using SPECT/CT within 30-60 minutes reflect the perfusion at the exact moment of injection, providing a snapshot of blood flow in the tumor.
Time frame: Within a one-week time frame, prior to chemotherapy initiation.
Patient-reported quality-of-life
This is an exploratory outcome to assess which patient reported outcomes are relevant to explore in future work. Quality-of-life parameters using the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30) have been collected as part of routine care (in conjunction with scan result oncology consults) since 2021. As such quality-of-life data is available for both groups through medical records. This well-validated, questionnaire comprises five functional scales, nine symptom scales or items and a global health status/quality of life scale. Values range from 0 to 100. Whether a higher score means a better or worse outcome depends on the specific scale type: higher scores indicate a better outcome for functional and global health scales, but a worse outcome for symptom scales.
Time frame: From enrollment and up to six months after chemotherapy
Patient-reported emotional well-being
This is an exploratory outcome to assess which patient-reported outcomes are relevant to explore in future work. In addition to patient-reported quality-of life (collected as usual care in conjunction with scan result oncology consults since 2021) the intra-infusion exercise group will also be asked to fill out the Hospital Anxiety and Depression Scale (HADS). This 14-item questionnaire is widely used in cancer and screens for anxiety and depressive states with values ranging from 0 to 21 for each individual subscale (anxiety and depression), or 42 for the combined total score. Higher scores mean a worse outcome, indicating higher levels of anxiety, depression, or overall psychological distress.
Time frame: From enrollment and up to six months post-treatment.
Experience and acceptability of intra-infusion exercise
A semi-structured interview will be carried out to explore patient-centered experience and acceptability of intra-infusion exercise.
Time frame: After completion of chemotherapy. As sarcomas are a heterogeneous group of cancers, chemotherapy regimens, including duration, will vary between participants.
Plan to share: Yes — Individual participant data that underlie the results reported in publications, after de-identification.
Supporting information: Study protocol, Statistical analysis plan
Time frame: After publication and up to five years.
Access criteria: Requests should be directed to the Principal Investigator's email, and will be available to researchers who provide a methodologically sound proposal (e.g. systematic review and meta-analysis).
Start is estimated for Jan 2027; primary completion for Oct 2028, 21 months later.
Of 144 non-industry interventional studies with no phase under Sarcoma, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 120. This study's planned 21 months is below that.
Counting every sponsor, half of 147 studies reached it within 59 months; a quarter within 34 and three quarters within 120.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.